Qihuang Pharmaceutical

Qihuang Pharmaceutical is a China-based biotechnology company specializing in the development of next-generation RNA-base editing therapies. The company's core technology platform focuses on recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR) enzymes to achieve precise and site-specific editing of mRNA transcripts. This approach aims to correct genetic mutations or modulate protein function without the permanent risks or off-target concerns associated with DNA-level genome editing. Headquartered in Hangzhou, Qihuang is currently advancing a pipeline of preclinical programs primarily focused on rare genetic metabolic disorders and liver-targeted conditions. The company is backed by prominent venture capital firms and represents a growing segment of the Chinese biotech industry dedicated to programmable RNA therapeutics.